当前位置: X-MOL 学术Ann. Rheum. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic
Annals of the Rheumatic Diseases ( IF 27.4 ) Pub Date : 2020-04-02 , DOI: 10.1136/annrheumdis-2020-217367
Francesca Romana Spinelli 1 , Fulvia Ceccarelli 2 , Manuela Di Franco 2 , Fabrizio Conti 2
Affiliation  

These days, the entire scientific community is facing the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emergency, characterised last 11 March by WHO as a pandemic. Social behaviour modification measures may somehow limit the spreading of the infection. However, in the case of an extremely contagious pathogen, the huge number of infected people may be a challenge for the health system. What if there was a prophylactic drug? In the light of their in vitro effect and early clinical results, antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been proposed for patients with SARS-CoV2-related pneumonia (Covid-19) and are now included in the Chinese guidelines for the management of Covid-19 (version 7, 3 March 2020). Antiviral activity of antimalarials has been known for more than 10 years (see online supplementary text).### Supplementary data [annrheumdis-2020-217367supp001.pdf] Recently, Wang et al demonstrated that at low micromolar concentration CQ was …
更新日期:2020-04-02
down
wechat
bug